Newsfeed

This area is a possible form of presentation for the integration of news sources relating to listed companies.
The presentation level is a template based on short news services, where users can get a quick overview of the latest news. The detailed views enable further research if interested.

This newsfeed is a compilation of current news from direct connections of TopTier NewsWire services related to listed companies. This feed is for demonstration purposes only. Sector-specific news, public relations and product information can be accessed via the GICS portals > Sector Intelligence section.

US38341P1021
Reset filter
Do you already know our new terminal view? Click here.
FIGI: BBG00MVWLLM2
GOSS
Gossamer Bio Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Biotechnology · THEMEFOLIO: $HLTH
NAME
Gossamer Bio Inc
ISIN
US38341P1021
TICKER
GOSS
MIC
XNAS
REUTERS
GOSS.OQ
BLOOMBERG
GOSS US
Thu, 09.04.2026       Gossamer Bio
US38341P1021

Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming June 1, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Cla...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 9, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 09.04.2026       Gossamer Bio
US38341P1021

Philadelphia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 08.04.2026       Gossamer Bio
US38341P1021

Law Offices of Howard G. Smith reminds investors of the upcoming June 1, 2026 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WH...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Gossamer Bio
US38341P1021

"We firmly believe that we have accomplished this patient selection goal." That was the promise. The reality: a Phase 3 trial that failed its primary endpoint, and shareholders who lost over 80% of their investment in a single trading session.Levi & Korsinsky, LLP notifies investors in Gossamer Bio, Inc. (NASDAQ: GOSS) that a securities class a...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Gossamer Bio
US38341P1021

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (th...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 07.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 7, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Gossamer Bio, Inc. (NASDAQ: GOSS). Shareholders who purchased shares of GOSS during the class period listed are encouraged to co...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Gossamer Bio
US38341P1021

The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”). Gossamer investors have until June 1, 2026 to fil...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Gossamer Bio
US38341P1021

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026, inclusive (the “Class Period”). Gossamer investors have until June 1, 2026 to file a lead plaintiff motion.IF...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Mon, 06.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders wh...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 06.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 6, 2026 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Sun, 05.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) investors concerning the Company’s possible violations of the federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GOSS...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

Law Offices of Howard G. Smith announces an investigation on behalf of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN GOSSAMER BIO, INC. (GOSS), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Gossamer To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Gossamer between June 16, 2025 and February 20, 2026 and would like to discuss your legal rights, call Faruqi & Faruqi partner...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

Philadelphia, Pennsylvania--(Newsfile Corp. - April 3, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer" or the "Company") on behalf of investors who purchased or acquired Gossamer shares during the period from June 16, 2025 through February 20, 2026 (the...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of GOSS during the cla...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

LOS ANGELES, April 3, 2026 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Gossamer Bio, Inc. ("Gossamer" or "the Company") (NASDAQ: GOSS) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders wh...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 03.04.2026       Gossamer Bio
US38341P1021

NEW YORK, April 2, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Silent Ad
Fri, 03.04.2026       Gossamer Bio
US38341P1021

SAN DIEGO, April 2, 2026 /PRNewswire/ -- Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026.  Gossamer is a clinical stage biopharmaceutical company focused on the development and comme...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Gossamer Bio
US38341P1021

The Law Offices of Frank R. Cruz announces an investigation of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS) on behalf of investors concerning the Company’s possible violations of federal securities laws.IF YOU ARE AN INVESTOR WHO LOST MONEY ON GOSSAMER BIO, INC. (GOSS), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAIM TO...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 02.04.2026       Gossamer Bio
US38341P1021

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Invest...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Gossamer Bio
US38341P1021

Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Gossamer Bio, Inc. (NASDAQ: GOSS) securities between June 16, 2025 and February 20, 2026. Gossamer is a clinical stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatm...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 01.04.2026       Gossamer Bio
US38341P1021

Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More Likely NEW YORK, April 1, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Fahee...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 30.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 30, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Compa...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.03.2026       Gossamer Bio
US38341P1021

NEW YORK, March 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 25.03.2026       Gossamer Bio
US38341P1021

Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More Likely NEW YORK, March 25, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Fahe...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 23, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 19.03.2026       Gossamer Bio
US38341P1021

NEW YORK, March 19, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 18.03.2026       Gossamer Bio
US38341P1021

Gossamer Bio CEO Expressed Optimism About PROSERA Trial Outcome; the Study Missed Its Primary Endpoint Months LaterNEW YORK, March 18, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) shareholders suffered significant losses when the Company disclosed that its Phase 3 PROSERA study of seralutinib missed its primary 6-minute walk distance end...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 17.03.2026       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the fourth quarter and year ended December...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 16.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 16, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. (NASDAQ: GOSS) ("Gossamer Bio, Inc.") concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 12.03.2026       Gossamer Bio
US38341P1021

NEW YORK, March 12, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 09.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 9, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Compan...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.03.2026       Gossamer Bio
US38341P1021

NEW YORK, March 5, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 05.03.2026       Gossamer Bio
US38341P1021

Gossamer Bio Provided Forward-Looking Trial Guidance While Omitting the Heightened Statistical Threshold That Made a Miss More LikelyNEW YORK, March 4, 2026 /PRNewswire/ -- Gossamer Bio, Inc. (NASDAQ: GOSS) lost more than 60% of its value after the Company's Phase 3 PROSERA trial of seralutinib missed its primary endpoint. In May 2025, CEO Faheem...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 03.03.2026       Gossamer Bio
US38341P1021

New York, New York--(Newsfile Corp. - March 3, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Gossamer Bio, Inc. ("Gossamer Bio, Inc.") (NASDAQ: GOSS) concerning potential violations of the federal securities laws.Seralutinib was Gossamer Bio's lead pipeline candidate and the PROSERA study was the Compan...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Sun, 01.03.2026       Gossamer Bio
US38341P1021

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or “the Company”) (NASDAQ: GOSS) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 26.02.2026       Gossamer Bio
US38341P1021

NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. ("Gossamer" or the "Company") (NASDAQ: GOSS).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980....
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 23.02.2026       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS) a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced topline results for the PROSERA Phase 3 Study of seralutinib in patie...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 08.01.2026       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Tue, 09.12.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 24.11.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the follow...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.11.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Compensation Committee of Gossamer’s B...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Fri, 07.11.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that the Company will participate in the follow...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Wed, 05.11.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced its financial results for the third quarter end...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.09.2025       Gossamer Bio
US38341P1021

- Transaction designed to accelerate development of RT234 (vardenafil Inhalation powder), an investigational first-in-class, as-needed (PRN) treatment for PAH and PH-ILD - PALO ALTO, Calif., Sept. 25, 2025 /PRNewswire/ -- Respira Therapeutics, Inc. (Respira or the "Company"), a Samsara BioCapital portfolio company, today announced that it has ent...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Thu, 25.09.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced it has entered into an option agreement to acqu...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink
Mon, 22.09.2025       Gossamer Bio
US38341P1021

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced that five scientific presentations related to seralut...
Read more
Gossamer Bio
Technical Analysis Termsheets Terminal
Permalink